Suppr超能文献

共病对儿童强迫症患者帕罗西汀治疗反应的影响:在随机临床试验中使用排除标准是否有实证支持?

Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials?

作者信息

Geller Daniel A, Biederman Joseph, Stewart S Evelyn, Mullin Benjamin, Farrell Colleen, Wagner Karen Dineen, Emslie Graham, Carpenter David

机构信息

Obsessive Compulsive Disorder Program, Pediatric Psychopharmacology Research Program, Massachusetts General Hospital, & Harvard Medical School, Boston, Massachusetts 02114, USA.

出版信息

J Child Adolesc Psychopharmacol. 2003;13 Suppl 1:S19-29. doi: 10.1089/104454603322126313.

Abstract

OBJECTIVE

To examine the influence of psychiatric comorbidity on response and relapse rates in children and adolescents treated with paroxetine for obsessive-compulsive disorder (OCD).

METHODS

Patients responding following 16 weeks of treatment (phase I) were randomized to continued paroxetine or to placebo for 16 additional weeks (phase II). OCD response (phase I) and relapse (phase II) criteria were based on the Clinical Global Impression-Improvement Scale and the Children's Yale-Brown Obsessive Compulsive Scale. The presence of OCD and other psychiatric disorders was ascertained using the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version interview.

RESULTS

At entry, 193 of 335 (57.6%) patients had at least one psychiatric disorder in addition to OCD, and 102 of 335 (30.4%) had multiple other disorders. Although the response rate to paroxetine in the overall population was high (71%), the response rates in patients with comorbid attention deficit hyperactivity disorder, tic disorder, or oppositional defiant disorder (56%, 53%, and 39%, respectively) were significantly less than in patients with OCD only (75%) (intent-to-treat population, last observation carried forward analysis, p < 0.05). Psychiatric comorbidity was associated with a greater rate of relapse in the total patient population (46% for one or more comorbid disorders [p = 0.04] and 56% for two or more comorbid disorders [p < 0.05] vs. 32% for no comorbidity).

CONCLUSIONS

The results of these post hoc analyses show that comorbid illness adversely impacted response to pharmacotherapy with paroxetine in pediatric OCD and significantly increased risk of relapse following withdrawal from treatment. Continued paroxetine treatment reduced the relapse rates in all groups compared with placebo, including those with comorbid illness. Because pediatric OCD is frequently comorbid with other psychiatric disorders, results of randomized, controlled pediatric OCD trials that use multiple exclusion criteria may not generalize to more naturalistic OCD samples.

摘要

目的

探讨精神共病对接受帕罗西汀治疗的儿童及青少年强迫症(OCD)患者的缓解率及复发率的影响。

方法

治疗16周后有反应的患者(I期)被随机分为继续服用帕罗西汀组或安慰剂组,再治疗16周(II期)。OCD缓解(I期)及复发(II期)标准基于临床总体印象改善量表及儿童耶鲁布朗强迫症量表。使用学龄儿童情感障碍和精神分裂症的儿童定式检查问卷(现患及终生版访谈)确定OCD及其他精神障碍的存在情况。

结果

入组时,335例患者中有193例(57.6%)除OCD外至少患有一种精神障碍,335例中有102例(30.4%)患有多种其他障碍。尽管总体人群对帕罗西汀的缓解率较高(71%),但共患注意缺陷多动障碍、抽动障碍或对立违抗障碍的患者的缓解率(分别为56%、53%和39%)显著低于仅患OCD的患者(75%)(意向性治疗人群,末次观察结转分析,p<0.05)。精神共病与总体患者人群中更高的复发率相关(一种或多种共病障碍为46%[p = 0.04],两种或更多共病障碍为56%[p<0.05],无共病为32%)。

结论

这些事后分析结果表明,共病疾病对儿童OCD患者接受帕罗西汀药物治疗的反应产生不利影响,并显著增加停药后复发风险。与安慰剂相比,继续服用帕罗西汀可降低所有组的复发率,包括共病患者组。由于儿童OCD常与其他精神障碍共病,使用多种排除标准的随机对照儿童OCD试验结果可能不适用于更接近自然情况的OCD样本。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验